Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.

Oncologist · 2023 · PMC10322142 · PMID 37023705

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

15 Final OS results show a numerical trend favoring ipatasertib–paclitaxel (median OS 23.1 vs 18.4 months in ipatasertib vs placebo arm, stratified HR 0.62 [95% CI, 0.37-1.05]). 33 However, the Phase III IPATunity130 cohort A failed to show PFS benefit from the addition of ipatasertib to paclitaxel in patients with mTNBC harboring PIK3CA/AK

also in 337 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.